Novocure (NVCR) announced that Optune Lua has received a CE Mark for the treatment of adult patients with metastatic non-small cell lung cancer concurrently with immune checkpoint inhibitors or docetaxel who have progressed on or after a platinum-based regimen.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- NovoCure’s Optune Lua Gains CE Mark Approval
- NovoCure Ltd. (NVCR) Q1 Earnings Cheat Sheet
- Novocure price target lowered to $27 from $29 at Wedbush
- Positive Outlook for NovoCure: Strong Financial Performance and Promising Pipeline Developments Drive Buy Rating
- Novocure Reports Strong 2024 Revenue Growth